Waddell & Reed Financial’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
$27.9M Sell
518,499
-527,371
-50% -$30.4M 0.06% 324
2020
Q4
$51.2M Sell
1,045,870
-350,544
-25% -$16.2M 0.11% 224
2020
Q3
$45.4M Buy
1,396,414
+449,641
+47% +$14.3M 0.11% 214
2020
Q2
$24.5M Buy
946,773
+251,573
+36% +$6.27M 0.06% 293
2020
Q1
$16.9M Buy
695,200
+3,809
+0.6% +$95.9K 0.05% 310
2019
Q4
$19.3M Sell
691,391
-2,239
-0.3% -$58K 0.05% 350
2019
Q3
$16.6M Buy
+693,630
New +$18.5M 0.04% 361

Other funds holding VCYT

Waddell & Reed Financial's VCYT Position: Q1 2021 in Review

Waddell & Reed Financial reduced its Veracyte (VCYT) stake by 50% in Q1 2021, selling an estimated $30.4M and leaving 518,499 shares worth $27.9M. The position accounts for 0.06% of the portfolio, ranked #324.

Waddell & Reed Financial first reported a position in VCYT in Q3 2019 and has held it in 7 quarters since. The position peaked at $51.2M in Q4 2020. 235 funds tracked by Wall St. Rank hold VCYT as of Q1 2021.

  • Waddell & Reed Financial held 518,499 shares of Veracyte worth $27.9M as of Q1 2021.
  • Waddell & Reed Financial sold 527,371 Veracyte shares in Q1 2021, an estimated $30.4M.
  • Veracyte made up 0.06% of Waddell & Reed Financial's portfolio in Q1 2021, its #324 holding.
  • Waddell & Reed Financial first reported a position in Veracyte in Q3 2019 and has held it in 7 quarters since.
  • Waddell & Reed Financial's Veracyte position peaked at $51.2M in Q4 2020.
  • 235 funds tracked by Wall St. Rank held Veracyte as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.